|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||179.55 - 179.95|
|52-week range||39.82 - 179.95|
|PE ratio (TTM)||-25.85|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?
Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.
Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!
When Gilead Sciences (GILD) announced its acquisition of Kite Pharma (KITE), every company that had exposure to CAR-T --a type of cancer therapy that could allow for the creation of personalized drugs--got ...
Shares of Bluebird Bio (BLUE), a major player in the emerging gene therapy and CAR-T research markets, slumped more than 6% in morning trading Monday after receiving a key analyst downgrade.
Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
Novartis's new gene-modifying cancer therapy's $475,000-per-patient sticker price has drawn fire from advocate groups calling for cheaper drugs, but analysts said the Swiss drugmaker could initially struggle to break even. In a first for gene therapy in the United States, regulators approved Kymriah on Wednesday for patients up to 25 years of age who have relapsed or not been helped by previous treatment for B-cell acute lymphoblastic leukemia (ALL). While patient groups hailed the potent immunotherapy as a potential cancer game-changer, the Swiss drugmaker was also criticised for setting a price that places Kymriah among the most-expensive drugs ever.
U.S. regulators this week approved the first drug for a new type of cancer treatment, confirming a theme some stock pickers have found in biotech.
Jim Cramer explains why a report on Apple's September 12 product meeting ignited a larger trading theme than Hurricane Harvey's aftermath.
The euro has been gaining against the dollar despite ECB chief Mario Draghi making no comments about monetary policy at a key meeting of central bankers last week.
Gilead Sciences said that it was paying $11.9 billion to acquire Kite Pharma, a firm which could soon have the first cell therapies available to sufferers of certain types of cancers
Gilead Sciences on Monday agreed to buy Kite Pharma for about $11 billion in cash, Dow Jones reported, citing sources.
Jim Cramer flies through his take on callers' favorite stocks, including one interest-rate-bound play.
Corporate insiders are selling many more shares than they're buying. Some call that a sign that the rally is "breaking down."
A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers.